Palexia (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia, is an opioid analgesic presented as a tablet for oral use. It is indicated for the management of moderate to severe acute pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palexia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palexia as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tapentadol Hydrochloride is used in the management of pain through central nervous system pathways. It provides clinicians with options for several pain‑related conditions:

- Acute postoperative pain: Improves postoperative comfort and facilitates early mobilisation. - Chronic musculoskeletal pain: Reduces persistent pain intensity in conditions such as osteoarthritis. - Cancer‑related pain: Alleviates moderate to severe pain associated with malignant disease. - Neuropathic pain component: Offers benefit when a neuropathic component co‑exists. - Breakthrough pain: Provides rapid relief for episodic pain spikes in opioid‑tolerant patients.

Tapentadol Hydrochloride may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: Mild to moderate gastrointestinal upset. - Dizziness: Transient light‑headedness, especially on standing. - Constipation: Reduced bowel motility leading to infrequent stools. - Headache: Tension‑type or mild throbbing pain. - Somnolence: Generalised sleepiness or fatigue. - Dry mouth: Decreased salivary flow causing oral discomfort.

Serious or Rare Side Effects: - Respiratory depression: Reduced breathing rate, potentially life‑threatening. - Seizures: Convulsive episodes, particularly in patients with pre‑existing risk factors. - Severe hypotension: Marked drop in blood pressure causing dizziness or fainting. - Allergic reactions: Rash, pruritus, or anaphylaxis in susceptible individuals. - Dependence or abuse potential: Risk of misuse with prolonged exposure. - adrenal insufficiency: Rare endocrine disturbance affecting cortisol production.

When prescribing Tapentadol Hydrochloride, clinicians should consider several safety measures:

- Assess pain severity: Confirm that opioid therapy is appropriate for the level of pain. - Review medical history: Identify respiratory disorders, head injury, or substance‑use disorder. - Monitor for sedation: Observe patients for excessive drowsiness or impaired cognition. - Adjust for renal/hepatic impairment: Dose may need modification in reduced organ function. - Educate on constipation: Recommend dietary fibre, fluids and laxatives as needed. - Store at ambient temperature: Keep tablets tablets in the original pack.

Tapetn  

---

---  

---